BR112017020002A2 - COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT - Google Patents

COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT

Info

Publication number
BR112017020002A2
BR112017020002A2 BR112017020002-3A BR112017020002A BR112017020002A2 BR 112017020002 A2 BR112017020002 A2 BR 112017020002A2 BR 112017020002 A BR112017020002 A BR 112017020002A BR 112017020002 A2 BR112017020002 A2 BR 112017020002A2
Authority
BR
Brazil
Prior art keywords
antibody
entinostat
cancer
patient
administered
Prior art date
Application number
BR112017020002-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Goodenow Robert
Ordentlich Peter
Original Assignee
Syndax Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56977796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017020002(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syndax Pharmaceuticals, Inc. filed Critical Syndax Pharmaceuticals, Inc.
Publication of BR112017020002A2 publication Critical patent/BR112017020002A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
BR112017020002-3A 2015-03-20 2016-03-18 COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT BR112017020002A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562136303P 2015-03-20 2015-03-20
US62/136,303 2015-03-20
US201562137601P 2015-03-24 2015-03-24
US62/137,601 2015-03-24
PCT/US2016/023298 WO2016154068A1 (en) 2015-03-20 2016-03-18 Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer

Publications (1)

Publication Number Publication Date
BR112017020002A2 true BR112017020002A2 (en) 2018-06-19

Family

ID=56977796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020002-3A BR112017020002A2 (en) 2015-03-20 2016-03-18 COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT

Country Status (11)

Country Link
US (3) US11324822B2 (cg-RX-API-DMAC7.html)
EP (1) EP3270966B1 (cg-RX-API-DMAC7.html)
JP (3) JP2018508593A (cg-RX-API-DMAC7.html)
KR (1) KR20170124604A (cg-RX-API-DMAC7.html)
CN (1) CN107614011A (cg-RX-API-DMAC7.html)
AU (2) AU2016235434B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017020002A2 (cg-RX-API-DMAC7.html)
ES (1) ES2986548T3 (cg-RX-API-DMAC7.html)
IL (3) IL323063A (cg-RX-API-DMAC7.html)
MX (1) MX2017012113A (cg-RX-API-DMAC7.html)
WO (1) WO2016154068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
AU2016318136B2 (en) * 2015-09-02 2022-10-20 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
EP3400009A2 (en) * 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
RU2018130831A (ru) * 2016-01-28 2020-03-02 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JP7090611B2 (ja) * 2016-11-23 2022-06-24 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ－ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法
KR20240042244A (ko) 2017-05-19 2024-04-01 신닥스 파마슈티컬스, 인크. 조합 요법
JP2020533320A (ja) * 2017-09-08 2020-11-19 ４エスツェー アクチェンゲゼルシャフト 癌療法のための免疫チェックポイント調節薬と併用したｈｄａｃ阻害薬
WO2019191764A1 (en) * 2018-03-28 2019-10-03 Ensemble Group Holdings Methods of treating cancer in subjects having dysregulated lymphatic systems
CA3099702A1 (en) 2018-05-07 2019-11-14 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
EP3843718A1 (en) 2018-06-15 2021-07-07 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
WO2019240871A1 (en) 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with s-equol
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
TW202128224A (zh) * 2019-12-23 2021-08-01 大陸商信達生物製藥（蘇州）有限公司 抗ｐｄ－１抗體和組蛋白去乙醯化酶抑制劑的藥物組合及其用途、使用方法
WO2024222705A1 (zh) * 2023-04-25 2024-10-31 深圳微芯生物科技股份有限公司 用于治疗pd-l1表达阳性局部晚期或转移性nsclc患者的药物及其用途
WO2024238811A2 (en) * 2023-05-18 2024-11-21 Avstera Therapeutics Corp. Composition comprising hdac inhibitor and immune checkpoint inhibitor and methods for using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US20130150386A1 (en) 2011-12-09 2013-06-13 Syndax Pharmaceuticals, Inc. Methods for the treatment of lung cancer
US8987067B2 (en) * 2013-03-01 2015-03-24 International Business Machines Corporation Segmented guard ring structures with electrically insulated gap structures and design structures thereof
BR112016001420A2 (pt) * 2013-08-02 2018-01-23 Aduro Biotech Holdings Europe B V combinação de agonistas de cd27 e inibição pontual imune para estimulação imune
WO2015035112A1 (en) * 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
US9987258B2 (en) * 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
CA2955177A1 (en) * 2014-07-15 2016-01-21 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
EA201790834A1 (ru) * 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
US20180353602A1 (en) * 2015-06-29 2018-12-13 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
AU2016318136B2 (en) * 2015-09-02 2022-10-20 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy

Also Published As

Publication number Publication date
WO2016154068A1 (en) 2016-09-29
RU2017134315A (ru) 2019-04-03
EP3270966B1 (en) 2024-05-01
US20240398944A1 (en) 2024-12-05
NZ735686A (en) 2024-07-26
US11324822B2 (en) 2022-05-10
JP2018508593A (ja) 2018-03-29
EP3270966A1 (en) 2018-01-24
AU2016235434B2 (en) 2022-02-03
MX2017012113A (es) 2018-07-06
IL254529B1 (en) 2024-01-01
KR20170124604A (ko) 2017-11-10
AU2016235434A1 (en) 2017-10-12
US20230022573A1 (en) 2023-01-26
CA2980297A1 (en) 2016-09-29
IL254529B2 (en) 2024-05-01
IL254529A0 (en) 2017-11-30
EP3270966A4 (en) 2018-10-17
AU2022202954A1 (en) 2022-05-26
JP2021175754A (ja) 2021-11-04
IL307850A (en) 2023-12-01
HK1250142A1 (en) 2018-11-30
CN107614011A (zh) 2018-01-19
JP2024091945A (ja) 2024-07-05
IL323063A (en) 2025-10-01
RU2017134315A3 (cg-RX-API-DMAC7.html) 2019-09-12
ES2986548T3 (es) 2024-11-11
US20180078639A1 (en) 2018-03-22
JP7540980B2 (ja) 2024-08-27

Similar Documents

Publication Publication Date Title
JP7540980B2 (ja) がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ
WO2017004092A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
US11397184B2 (en) Selection of patients for combination therapy
US20190290759A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
US20240288425A1 (en) Selection of patients for combination therapy
CA2980297C (en) Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer
RU2796903C2 (ru) Комбинация ингибитора hdac и анти-pd-1 антитела для лечения рака
HK1250142B (en) Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer wherein the combination does not comprise 5-azacytidine

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]